RX Stock Overview
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
BioSyent Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$7.03|
|52 Week High||CA$10.00|
|52 Week Low||CA$6.24|
|1 Month Change||-0.99%|
|3 Month Change||-12.67%|
|1 Year Change||-19.20%|
|3 Year Change||-2.23%|
|5 Year Change||-28.27%|
|Change since IPO||1,462.22%|
Recent News & Updates
BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share PriceApr 14
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMar 19
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?Mar 17
BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last YearFeb 18
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too ConservativeJan 28
BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value EstimateJan 07
BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?Dec 17
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?Dec 02
|RX||CA Pharmaceuticals||CA Market|
Return vs Industry: RX exceeded the Canadian Pharmaceuticals industry which returned -46.8% over the past year.
Return vs Market: RX underperformed the Canadian Market which returned -3.4% over the past year.
|RX Average Weekly Movement||7.9%|
|Pharmaceuticals Industry Average Movement||14.1%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||18.2%|
|10% least volatile stocks in CA Market||4.1%|
Stable Share Price: RX is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: RX's weekly volatility (8%) has been stable over the past year.
About the Company
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum.
BioSyent Inc. Fundamentals Summary
|RX fundamental statistics|
Is RX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RX income statement (TTM)|
|Cost of Revenue||CA$5.20m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.51|
|Net Profit Margin||22.17%|
How did RX perform over the long term?See historical performance and comparison